Dagmara Klasa-Mazurkiewicz

Changes in mRNA and protein levels of human HtrA1, HtrA2 and HtrA3 in ovarian cancer

Joanna Narkiewicz, Dagmara Klasa-Mazurkiewicz, Dorota Żurawa‐Janicka et al. · Clinical Biochemistry · 2008 · 71 citations

Endocrine-related Cancer, Oncogenic Agent, Medicine +10

Continuous, daily levonorgestrel/ethinyl estradiol vs. 21-day, cyclic levonorgestrel/ethinyl estradiol: efficacy, safety and bleeding in a randomized, open-label trial

A. Teíchmann, Dan Apter, Janusz Emerich et al. · Contraception · 2009 · 48 citations

Open-label Trial, Hormonal Contraceptive, Daily Levonorgestrel/ethinyl Estradiol +8

Clinical significance of VEGFR-2 and VEGFR-3 expression in ovarian cancer patients.

Dagmara Klasa-Mazurkiewicz, Mirosław Jarząb, Tomasz Milczek et al. · PubMed · 2011 · 43 citations

Pathology, Gynecology, Vegfr-3 Tissue Expression +16

Maspin overexpression correlates with positive response to primary chemotherapy in ovarian cancer patients

Dagmara Klasa-Mazurkiewicz, Joanna Narkiewicz, Tomasz Milczek et al. · Gynecologic Oncology · 2009 · 23 citations

Endocrine-related Cancer, Medicine, Gynecology +10

Selective gene expression profiling of mTOR-associated tumor suppressor and oncogenes in ovarian cancer

Piotr Laudański, Oksana Kowalczuk, Dagmara Klasa-Mazurkiewicz et al. · Folia Histochemica et Cytobiologica · 2011 · 14 citations · Full text